Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
CRDF filed a patent for "cancer treatment using lsd1 inhibitors and plk1 inhibitors" on Tue, May 14, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
